Is transcutaneous electrical nerve stimulation (TENS) on the forehead safe for an adult with episodic migraine, what are the risks, and what intensity should be used?

TENS on the Forehead for Migraine: Safety, Risks, and Intensity

Transcutaneous electrical nerve stimulation (TENS) applied to the forehead (specifically targeting the supraorbital/trigeminal nerves) is safe and effective for acute migraine treatment in adults, with minimal risks limited to mild local skin irritation, and should be used at the strongest tolerable intensity (typically described as "strong non-painful" stimulation) for optimal pain relief.

Evidence Base and Context

The most recent American College of Physicians guidelines for acute episodic migraine 1 focus exclusively on pharmacologic treatments and do not address TENS or other neuromodulation devices. However, the 2024 VA/DoD guidelines 2 note that evidence for neuromodulation in migraine is limited with small sample sizes, resulting in insufficient evidence to make formal recommendations—though this reflects the conservative nature of guideline development rather than evidence of harm.

Safety Profile

TENS applied to the forehead is remarkably safe:

• No serious adverse events have been reported across multiple controlled trials 3, 4, 5
• Minor adverse events are rare, with only 5 minor events reported in one 106-patient trial 5
• The most common side effect is mild, transient local skin irritation or tingling
• No contraindications exist for most patients with episodic migraine
• The device is non-invasive and does not carry risks associated with systemic medications

This safety profile makes TENS particularly valuable for patients who cannot tolerate or have contraindications to standard pharmacologic treatments.

Efficacy Evidence

The research evidence demonstrates meaningful clinical benefit:

• Acute treatment: A 2016-2017 randomized controlled trial showed TENS reduced pain intensity by 59% versus 30% with sham treatment (p<0.0001) after 1 hour of stimulation 5
• Preventive use: A 2022 meta-analysis found TENS reduced headache frequency by 2.81 days per month in episodic migraine (95% CI 2.18-3.43) 6
• Real-world effectiveness: A 2021 home-use trial demonstrated statistically significant pain reduction and improved functional disability with self-applied TENS during migraine attacks 3
• Patients refractory to topiramate showed significant reductions in headache days, headache intensity, and acute medication use after 3 months of TENS 4

Optimal Intensity Settings

Use the strongest tolerable intensity that remains non-painful:

• A 2011 dose-response study definitively showed that "strong non-painful" TENS produces significantly greater hypoalgesia than sensory threshold, below-threshold, or placebo stimulation 7
• The correlation between current amplitude and pain relief was significant (r²=0.33, p=0.003), demonstrating a clear dose-response relationship 7
• Practical application: Instruct patients to increase the intensity until they feel a strong but comfortable tingling/buzzing sensation without pain or muscle contraction
• Most studies used 80-100 Hz frequency for acute treatment 7, 5
• A recent 2025 study on occipital nerve stimulation found 100 Hz programs were preferred over 10 Hz by patients 8

Treatment Protocol

For acute migraine attacks:

• Apply electrodes to the forehead over the supraorbital nerves (above eyebrows)
• Set frequency to 80-100 Hz
• Titrate intensity to the strongest non-painful level
• Treat for 60 minutes for acute attacks 5
• Can be used at migraine onset or during established attacks

For preventive use:

• Stimulate for 30 minutes twice daily at minimum 4, 8
• Continue for at least 8-12 weeks to assess efficacy 4, 8

Clinical Decision-Making Algorithm

When to consider TENS:

1. First-line consideration for patients who:

   • Cannot tolerate NSAIDs, acetaminophen, or triptans
   • Have contraindications to standard pharmacologic therapy
   • Prefer non-pharmacologic approaches
   • Are pregnant or breastfeeding (where medication options are limited)

2. Adjunctive therapy for patients with:

   • Inadequate response to pharmacologic treatment alone
   • Desire to reduce medication frequency
   • Risk of medication overuse headache

3. Not a replacement for evidence-based pharmacologic therapy in patients who respond well to medications, but can be used concurrently

Important Caveats

• TENS is not mentioned in the 2025 ACP guidelines [1-1], which prioritize pharmacologic treatments (NSAIDs, acetaminophen, triptans, gepants) as first-line therapy based on stronger evidence
• The evidence base for TENS, while positive, consists of smaller trials compared to medication studies
• Individual response varies: approximately 36-42% of patients achieve clinically meaningful improvement 4, 8
• TENS should complement, not replace, appropriate pharmacologic management when medications are effective and tolerated
• The device requires patient education and proper electrode placement for optimal results

Practical Implementation

• Standard TENS units are low-cost and widely accessible
• Patients can self-apply treatment at home
• No prescription required for over-the-counter TENS devices
• Compliance is higher among patients who experience early benefit 4
• Consider a 3-month trial period to adequately assess individual response

Bottom line: TENS on the forehead is a safe, low-risk option with demonstrated efficacy for both acute and preventive migraine treatment, used at the strongest tolerable non-painful intensity (80-100 Hz), particularly valuable for patients who cannot use or do not respond adequately to standard pharmacologic treatments.